Eighth Annual CTO Summit and Left Main Coronary Interventions Course to be held Feb. 14-16, in New York City

Joint meeting will be held Feb. 14-16, 2011, in New York City

WHAT: The Eighth Annual Chronic Total Occlusion Summit and Left Main Coronary Interventions Course is a three-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions and left main coronary interventions. Topics at this year's summit will include:

  • When and why to open a chronic total occlusion (CT0)
  • Left main percutaneous coronary intervention (PCI) vs. coronary artery bypass graft (CABG) surgery: Patient selection
  • CTO angioplasty: Antegrade vs. retrograde approaches, wire and device selection, and essential techniques and tips
  • Basic and advanced imaging and physiologic lesion assessment to improve procedural results and late outcomes
  • Pharmacology essentials
  • Minimizing and managing complications
  • Left main intervention: Managing the distal bifurcation, when to debulk and use hemodynamic support, approach to left main and multivessel disease, stent selection, and ongoing trials

WHY: Leading practitioners of percutaneous coronary intervention must become experts at recanalizing chronic total occlusions, and with advanced techniques, success rates greater than 90% may be obtained. Additionally, stenting of the unprotected left main coronary artery has emerged as a viable alternative to surgery in selected patients but requires a special skill set and understanding of anatomy, imaging, hemodynamic support, and adjunctive devices.

This year's conference will emphasize both advanced techniques and evidence-based medicine, with a heavy reliance on live case transmissions featuring the world's leading experts in left main and CTO stenting.

WHEN: February 14 -16, 2011

WHERE: New York Marriott Marquis Hotel
New York, NY

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients